Chiltern Opens New Office in Argentina
Chiltern International Limited (Chiltern), a global clinical contract research organization (CRO) announced that it has opened a new office in Argentina.
Oscar Podesta, Chiltern Executive Director, Latin America, leads this endeavor.“Our office, strategically located in suburban Pilar, is a natural next step to our development in Argentina. The office’s state-of-the-art facilities and technology are designed to support our growing client needs in Mexico, Chile, Peru and throughout all Latin America, complementing Chiltern’s Sao Paulo, Brazil office,” commented Oscar.
“Chiltern’s opening of the Buenos Aires office in 2010 continues our globalization effort following the opening of four new offices in 2009,” stated Glenn Kerkhof, Chiltern CEO. “Chiltern’s strong presence in Argentina, Brazil, Mexico and the entire Latin American region demonstrates our commitment to providing high quality services globally.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
